Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK)

NCT05527717 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT05527717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05527717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK)
Lead sponsor
Samsung Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
November 16, 2022
Completion date
December 31, 2028
Enrollment
560 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction, cardiogenic shock, extracorporeal membrane oxygenation, multi vessel coronary artery disease